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AbstrACt
Objectives To build up and test a Monte Carlo simulation 
procedure for the investigation of overdiagnosis in breast 
screening programmes (BSPs).
Design A Monte Carlo tool previously developed has been 
adapted for obtaining the quantities of interest in order to 
determine the overdiagnosis: the annual and cumulative 
number of cancers detected by screening, plus interval 
cancers, for a population following the BSP, and detected 
clinically for the same population in the absence of 
screening. Overdiagnosis is obtained by comparing these 
results in a direct way.
results Overdiagnosis between 7% and 20%, depending 
on the specific configuration of the programme, have been 
found. These range of values is in agreement with some of 
the results available for actual BSPs. In the cases analysed, 
a reduction of 11% at most has been found in the number 
of invasive tumours detected by screening in comparison 
to those clinically detected in the control population. It has 
been possible to establish that overdiagnosis is almost 
entirely linked to ductal carcinoma in situ tumours.
Conclusions The use of Monte Carlo tools may facilitate 
the analysis of overdiagnosis in actual BSPs, permitting to 
address the role played by various quantities of relevance 
for them.
IntrODuCtIOn
Breast screening programmes (BSPs) have 
become usual in developed countries and this 
has stimulated an intense debate about the 
potential risks and benefits for the women 
invited to follow them. One of their main 
consequences is the change of the breast 
cancer incidence in the population. This is 
due to the advance in the diagnosis of the 
disease, which increases the incidence rates 
at earlier ages. In addition, other facts, such 
as those derived from the use of hormone 
replacement therapy, may modify the preva-
lence and, eventually increase the underlying 
incidence.1 
However, this apparent incidence excess 
should not be confused with overdiagnosis, 
an aspect that, together with overtreatment, 
has focused part of the discussion in the 
last years.2 BSPs are supposed to enhance 
the ability for detecting tumours in their 
early growth stages, which are those asso-
ciated with a better prognosis and survival 
of patients. However, some of the cancers 
found in the screening grow so slowly that 
they would never manifest clinical symptoms 
before the women will die due to causes 
other than breast cancer. The detection of 
these tumours is called overdiagnosis of the 
BSP.2 3 Due to the impossibility of knowing, 
a priori, the cancer evolution, the available 
therapeutic machinery is switched on and the 
strengths and limitations of this study
 ► Overdiagnosis values quoted in the present study 
may be slightly overestimated because we have 
chosen 70 years as the maximum age of the women 
following the breast screening programmes (BSPs).
 ► Simulations require the use of data corresponding 
to a reference population (eg, the breast cancer in-
cidence) that may differ to some extent with those 
of specific populations and that introduces a certain 
uncertainty in the results.
 ► The use of the present Monte Carlo tool permits to 
investigate the influence of the parameters defining 
the BSP as well as their results (such as overdigano-
sis) without involving actual populations and avoid-
ing the economical, logistic and ethical problems 
that it usually entails.
 ► Specifically, overdiagnosis may be addressed in an 
easy way overcoming the limitations of the random-
ized essays in this respect.
 ► Possible changes in the diagnostic or procedural 
methodologies can be included in the simulation, 
thus allowing to anticipate the results of the new 
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women overdiagnosed become subject of overtreatment 
(eg, surgery, radiotherapy and even chemotherapy) with 
the consequent possible adverse effects, even in those 
cases that would not evolve towards malignancy. Besides, 
some degree of spontaneous remission or asymptomatic 
latency, in case of invasive cancers, has been observed, 
and this would increase overdiagnosis.4 5
The determination of the overdiagnosis extent is in 
practice of a complicated task. Some estimations have 
been provided on the basis of the results obtained in BSPs 
running after several years. In this case, overdiagnosis is 
obtained by comparing the incidence of breast cancer in 
the women following the BSP with that in a population 
with similar characteristics (age, exposure to risk factors 
for breast cancer, availability of treatment, follow-up until 
death, etc.) and that does not undergo screening. Overdi-
agnosis would be linked to the cancer excess in the BSP 
group but the direct interpretation of the incidence data 
in women following a BSP is not straightforward because 
of the fluctuations in the incidences of the populations 
that are compared, the differences in the configura-
tions of the BSPs considered (age ranges of the women 
following the programme, mammography frequencies, 
follow-up times), as well as the ways how the lead time 
(understood as the time between the tumour detection 
by screening and the clinical one) is considered.2 6
A priori, a most consistent estimate of overdiagnosis 
may be obtained in combined analyses of the results of 
various randomised controlled trials (RCTs). However, a 
huge variability in the quoted overdiagnosis data, mainly 
due to different methodologies in observational studies, 
has been pointed out.6 7 In any case, the RCTs developed 
to date8–15 were not designed to determine overdiag-
nosis and, as most of them began in the 1980s, have not 
included most of the recent advances in therapy and have 
not taken into account the impact of the higher image 
quality and the reduction in the detection thresholds on 
it.
In these circumstances, Monte Carlo simulation 
appears to be as a good alternative to overcome the 
difficulties pointed out. In previous works,16–18 we have 
developed a mammographic screening model based 
on Monte Carlo techniques and aiming at evaluating 
screening programmes. This simulation tool has allowed 
us to reproduce the results of actual BSPs concerning the 
invasive/in situ tumour detection rates with and without 
screening, the ranges of interval cancers, and other 
magnitudes associated with detection. By introducing the 
survival following local-regional treatment has enabled us 
to make estimates of the mortality reduction attributable 
to BSPs. Finally, the internal validity of the main RCTs 
included in the Cochrane meta-analysis3 was analysed by 
using the Monte Carlo tool adequately adapted to take 
into account the specific characteristics of each of them. 
In all the situations studied, the Monte Carlo simulation 
has proven to be an efficient instrument.
The purpose of the present work is to develop a new 
Monte Carlo tool to investigate the overdiagnosis of BSPs 
according to their particular configurations, these are 
age ranges of the women following the programme and 
mammography frequencies. To do that we have used the 
tool previously built up and tested16 that involves generic 
distributions that may be adapted to each specific popu-
lation in order to reach enough precision in the simula-
tion. The programme will provide us with the annual and 
cumulative number of cancers detected by screening, as 
well as the number of cancers clinically detected during 
the programme running (interval cancers) of the popu-
lation undergoing screening. The comparison of these 
results with those obtained for the same population in 
the absence of screening has allowed us to estimate the 
overdiagnosis in a direct way.
MAterIAl AnD MethODs
Our Monte Carlo tool allows carrying out simulations 
based on a minimum number of parameters having 
clinical or physical significance: tumour average size for 
symptomatic detection, mammography sensitivity (as a 
function of the thickness, histological type and density 
of the breast) and the proportion of invasive/in situ 
tumours. It is worth reminding the differences between 
these two histological types of cancers entering in our 
analysis. Ductal carcinoma in situ (DCIS), or intraductal 
carcinoma, involves the clonal proliferation of malig-
nant cells. They grow in the mammary duct lumens, do 
not invade the adjacent breast stroma and are usually 
diagnosed by mammography. On the contrary, invasive 
tumours do multiply in normal tissues and constitute 
much of the cases of the clinically detected breast cancers. 
Besides, we do not include any ad-hoc assumption such as 
that related to the higher aggressivity of tumours in their 
early growth stages.
Other simulation models are either overparameterised 
or based on distributions of parameters that are difficult 
to observe or show non-negligible correlations with the 
mammography sensitivity.19 Other approaches, such as 
those linked to Markov models, may generate results that 
strongly depend on the defined states.20
In the simulation tool we developed,16 that is the base 
of the present Monte Carlo approach, the history of each 
woman participating in a BSP is simulated individually, 
considering a model that includes parameters and char-
acteristics that may be gathered in one of the following 
categories.
 ► Parameters describing the target population of the 
BSP. Here we have the incidence distribution of 
breast cancer as a function of the age of the women. 
In our simulations we have used that of the Canary 
Islands before BSP as representative of an occidental 
population not submitted to screening. As the inci-
dence actually needed is that of the tumour onset, 
the incidence curve was shifted towards smaller ages 
using the average time between the tumour detection 
by any diagnostic technique and the tumour onset, 
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 ► Tumour properties that influence the probability of 
detection by mammography. Tumour size, histolog-
ical type and breast density are the three fundamental 
characteristics in this group. In addition, a model 
describing the evolution of the tumour size as a func-
tion of time and a model of the detection probability 
of breast cancer by mammography are required.
 ► Configuration of the BSP. Here we included the 
frequency of mammography, the age range of the 
women participating in the programme and the 
follow-up time for each participant.
The simulation of a history begins by sampling, within 
the corresponding population distribution, the age of a 
candidate to participate in the BSP. If the age obtained 
is within the range established for the virtual BSP, the 
women history continues by sampling whether the 
woman has developed a cancer at some moment since 
her birth. This is done according to the cumulative inci-
dence distribution. If the answer is affirmative, then the 
women breast density, the initial histological type of the 
tumour, the moment when it occurred and its size when 
the woman enters into the BSP are obtained by sampling 
the corresponding distributions. It is worth pointing out 
that both the tumour histological type and the breast 
density may change throughout the simulated history. 
The histological type may evolve from DCIS to invasive 
cancers. Also the breast density may reduce with age. 
These transitions are hypotheses taken into account in 
our model.
The moment at which the tumour arises is sampled 
according to the incidence curve, which shows the 
probability of tumour occurrence as a function of the 
woman age. The tumour size is estimated by using a real-
istic tumour growth model that describes the increase 
of the tumour diameter with the time elapsed since its 
inception. This growth is simulated by using a model21 
with a single free parameter that we assume to follow a 
log-normal distribution, an initial proportion of invasive/
DCIS tumours, and given transition probabilities between 
these two tumour histological types. This proportion is 
chosen according the results obtained for detection in 
the various screening rounds. No additional hypotheses 
about tumour evolution are included.
In those cases in which women have developed a 
tumour, the detection probability is sampled to consider 
whether the tumour is detected or not after the mammog-
raphy. For women who do not present disease, the spec-
ificity is used. If a true positive case occurs, the history 
is finished and a new one is started. In any other case, 
successive rounds are simulated either because the 
tumour was not detected in the previous one (false nega-
tive) or the woman is healthy but continues in the BSP 
until the age limit is reached (true negative). If, in this 
last case, the woman was erroneously classified as positive, 
we would deal with a false positive case and it is under-
stood that the woman is called again for a further test that 
will confirm the error in the diagnosis and that she will 
continue within the BSP.
In false negative cases, which suppose the continu-
ation of the history, the simulation takes into account 
the growth of the tumour between the different rounds, 
including the probability of clinical detection between 
them. This means that interval cancers are considered. 
Also the possible changes in the tumour histological type 
and breast density are taken into account. Likewise, for 
the cases of healthy women, the probability of cancer 
occurrence during follow-up is simulated.
With this methodology, the Monte Carlo tool permits 
to simulate the introduction of a BSP in a given popu-
lation, carry out its follow-up during a certain time and 
determine with the selected periodicity the total number 
of tumours detected by screening in the sample of women 
that attend the programme, as well as those detected clin-
ically (interval cancers if they occur in women who follow 
the BSP). If the prevalence of breast cancer is stable over 
time, the incidence curves corresponding to the popu-
lation undergoing screening should converge, after a 
time of the order of the lead time, to those found for 
the same population without screening, and the whole 
procedure would not show overdiagnosis. If this does not 
happen, and after the lead time, the two cumulative inci-
dence curves would remain parallel and the difference 
between both would provide us with an estimate of the 
overdiagnosis.






















  is the cumulative number of cancers 
detected in women who have followed the BSP during 




  is the 
cumulative number of tumour detected clinically in an 
equivalent group of women who have not followed a BSP, 
 tc  is the duration of the BSP or time course and  tl  is a 
time required to avoid the transient period associated to 
the lead time. Except for a very small number of cancers, 
the average lead time is ~3–4 years2 and we have consid-
ered  tl = 10 years .
In our simulations we ran 50 million of woman histories 
in each BSP. Two age ranges [al,au] = [50,70] and [40,70] 
(with age values given in years) were analysed with  tc = 10  
and 20 years, respectively. Time intervals between consec-
utive mammographies of  tint = 1 , 2 and 3 years were 
considered. In all cases simulated, an attendance rate of 
100% was assumed, though estimations for 80% atten-
dance were also performed.
The first running year of the BSP, all women with ages 
in the selected age range [al,au] enter the programme; in 
the following years, women who reach the minimum age 
of participation al are incorporated. They are followed 
within the BSP until they reach au. If the programme 
finishes, woman’s histories continue to be simulated, 
considering the possibility of tumour clinical detection. 
In our simulations we chose 20 years for this period after 
the programme: this permitted estimating the time neces-
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Patient and public involvement
The present study deals with a Monte Carlo simulation. 
Then, neither patients nor public were involved.
results
Figure 1 shows the cumulative incidences for invasive 
plus DCIS tumour, normalized to the average number of 
women participating in the BSP, (per thousand women), 
as a function of the time elapsed since the beginning of 
the BSP, for the configurations of [50-70] with  tc = 10  
years (panel 1a) and [40-70] with  tc = 20  years (panel 
1b). For these configurations, the results obtained for 
mammography frequencies  tint = 1  (green solid circles), 
2 (blue solid squares) and 3 (red solid triangles) years 
are shown. The attendance is assumed to be 100%. Open 
squares correspond to the values found for the popula-
tion of women who do not followed the BSP.
The overdiagnosis estimates for 100% attendance, 
calculated according to equation (1), are shown in table 1.
The corresponding incidences for invasive plus DCIS 
tumours, normalised to the average number of women 
participating in the BSP and for 100% attendance, are 
shown in figure 2.
Finally, in figure 3 the cumulative incidence for invasive 
cancers in the screened woman sample for  tint = 1  year and 
100% attendance (green solid circles) is compared to the 
results obtained for a population of women who did not 
follow a BSP (open squares). The values are normalised 
to the average number of women participating in the BSP.
DIsCussIOn
The effect of the overdiagnosis is clearly seen in figure 1: 
once a time equal to the lead time  tl = 10  years has passed 
after the BSP finished (this means, respectively, 20 and 30 
years after the beginning of the programme for the two 
configurations studied), the results obtained in the case 
of the women who have followed the BSP behave parallel 
to those of the unscreened woman.
As shown in table 1, the corresponding overdiag-
nosis estimates found for the [50–70] configuration are 
significantly larger (between 15% and 21%) than those 
obtained for the [40–70] one. This is due to the fact that 
the tumour detection by screening at earlier ages, as it 
occurs in the second configuration, would have more 
time to grow and reach a size exceeding the clinical detec-
tion threshold in the absence of screening.
On the other hand, and as it was expected, the increase 
of the time interval between mammographies reduces 
the overdiagnosis, the reduction being ~40% when  tint  
changes from 1 to 3 years.
Figure 1 Cumulative invasive + ductal carcinoma  in 
situ  tumour incidence, normalised to the average number 
of women participating in the breast screening programme 
(BSP), as a function of the time elapsed since the beginning 
of the BSP. Solid symbols show the results obtained for 
the configurations (A) [50–70] with a BSP duration of 
 tc = 10  years and (B) [40–70] with  tc = 20  years, with 100% 
attendance. The values corresponding to intervals between 
mammographies of  tint = 1 , 2 and 3 years are shown with 
green solid circles, blue solid squares and red solid triangles, 
respectively. Open squares indicate the results found for the 
woman population who do not follow the BSP.
Table 1 Values of overdiagnosis, as defined in equation (1), for the two configurations studied and the three mammography 
intervals  tint  considered in each case
 tint 
Overdiagnosis
[50,70] years;  tc = 10  years [40,70] years;  tc = 20  years
100% attendance 80% attendance 100% attendance 80% attendance
1 year 0.200±0.009 0.14 0.168±0.005 0.13
2 years 0.150±0.010 0.10 0.123±0.005 0.07
3 years 0.115±0.007 0.06 0.100±0.005 0.07
Values shown for 100% attendance were obtained with the Monte Carlo simulation tool; those for 80% attendance are estimations (see text 
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When the BSP finishes (after 10 years in the case of the 
configuration [50–70] and 20 years for the [40–70] one of 
its beginning), a transient period occurs. In figure 1 this is 
better seen in the case of  tint = 1  year (green solid circles) 
and it shows up as a change in the slope of the corre-
sponding data. This behaviour may be observed in a more 
clear way by looking at the corresponding incidences, shown 
in figure 2. Therein the trend described appears as a strong 
reduction of the incidence rate and is a consequence of the 
detection deficit once the BSP is no longer active. As we 
can see, the incidence rate requires about 10 years to reach 
the incidence corresponding to the unscreened population 
(shown with open squares). It is worth mentioning that the 
reduction observed is inherent to the BSP itself and it occurs 
even if overdiagnosis is absent. To isolate in the incidence 
curves these changes from those due to overdiagnosis, it is 
mandatory waiting for the lead time  tl = 10  years after the 
BSP has finished.
As seen in figure 3, for the configuration [50-70], the 
cumulative incidence for invasive cancers in the screened 
woman sample (shown by green solid circles in the panel 
3a) coincide with that obtained for the reference popula-
tion of women not following a BSP (open squares) after 
a period of ~5 years once the programme has finished. As 
the number of invasive tumours is the same in the popula-
tions with and without screening, the overdiagnosis above 
discussed relies completely on DCIS tumours. The same 
does not occur in the case of the configuration [40-70] 
(panel 3b) where a deficit of 11% in the cumulative inci-
dence of invasive tumours with respect to the unscreened 
population is found after BSP finished.
Once the importance of DCIS tumours in overdiag-
nosis has been pointed out, it is worth noting that it is 
not a consequence of a slower growth of these tumours 
compared with invasive ones, since our model does not 
include any difference according to their histological 
type. The reason is rather that there is a greater abun-
dance of DCIS cancers in the early stages in which they 
can be efficiently detected by screening.
Figure 2 Invasive+ductal carcinoma in situ tumour 
incidence, normalised to the average number of women 
participating in the breast screening programme (BSP), 
as a function of the time elapsed since the beginning of 
the BSP. Solid symbols show the results obtained for the 
configurations (A) [50–70] with a BSP duration of  tc = 10  
years and (B) [40– 70] with  tc = 20  years, with 100% 
attendance. The values corresponding to intervals between 
mammographies of tint=1, 2 and 3 are shown with green 
solid circles, blue solid squares and red solid triangles, 
respectively. Open squares indicate the results found for the 
woman population who do not follow the BSP.
Figure 3 Cumulative incidence for invasive tumours, 
normalised to the average number of women participating 
in the breast screening programme (BSP), as a function of 
the time elapsed since the beginning of the BSP. Green solid 
circles show the results obtained for the configurations (A) 
[50–70] with a BSP duration of  tc = 10  years and (B) [40–70] 
with  tc = 20  years, with an interval between mammographies 
of  tint = 1  year and 100% attendance. Open squares indicate 
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As said above, overdiagnosis estimations from actual 
BSPs are difficult. Puliti et al22 analysed 13 observational 
studies and concluded that overdiagnosis would reach up 
to 10%. In the case of the British National Health System 
BSP, with a follow-up of 20 years and for women older than 
50 years,2 the mammographic screening avoided a death 
each 250 invited women. Therefore, assuming an accep-
tance/participation rate of around 80% and a detection 
rate in the incidence rounds of 4 cancers detected per 
1000 women and year, one would have 3 cases of overdi-
agnosis/overtreatment per death avoided, that is, 1% of 
women invited to BSP are expected to be overdiagnosed.
The situation of the RCT estimations is also unclear. 
The Cochrane report established an absolute risk of 
overdiagnosis/overtreatment of 0.5%.3 Much smaller 
values,~0.025% per year, were established by Moss23 
according again to the data of the Canadian trials,9 10 while 
for the relative risk in the intervention arms of these RCTs 
he found values between 11% and 14%. The reasons of 
these discrepancies may be linked to the serious method-
ological problems shown by these RCTs.24
On the other hand, the 2009 revision for the US Preven-
tive Task Force25 quoted that overdiagnosis was within 1% 
and 10%.
Testing the results of these actual BSPs or RCTs with 
our Monte Carlo tool would require detailed simulations 
in which the various specifications of each of them are 
included. In the case of BSPs, one of the main inputs is 
the attendance that in our calculations has been assumed 
to be 100%. However, it is possible to estimate the overdi-
agnosis for lower attendances using the results we have 
obtained by assuming that the number of detected 
tumours remains approximately constant after the 
screening has finished. In table 1 the values obtained in 
this way for 80% attendance are shown. A smaller atten-
dance give rise to lower values of the overdiagnosis: a 
reduction of ~5% has been found for 80% attendance with 
respect to 100% one, the overdiagnosis ranging between 
7% and 14% depending on the configuration. These esti-
mations give an idea of the magnitude of overdiagnosis in 
BSPs with attendances around 80%.
To finish, it should be noted that our simulations may 
be affected by some limitations because we have not the 
incidence curves corrected by the average detection time 
for women over 70 years and the simulated histories 
stopped at that age. This may imply a small overestima-
tion of overdiagnosis. On the other hand, the fact that 
the simulations carried out require information corre-
sponding to a reference population (eg, the breast cancer 
incidence) introduces a certain uncertainty in the results 
because these data may differ to some extent with those 
of the specific populations investigated.
COnClusIOns
We have developed a model based on Monte Carlo simu-
lation techniques that allows us to reproduce consistently 
the known results about overdiagnosis on BSPs. It varies 
from 7% to 20% depending the programme configu-
ration (age range of women involved and frequency of 
mammography).
It has been found that, after the end of the screening 
programme, the incidence of invasive cancers is similar to 
that found for an unscreened control group: this implies 
that overdiagnosis is mainly associated with DCIS tumours. 
This is due to the fact that this type of cancers are more 
abundant than the invasive ones when they reach the size 
that make them to be detectable by mammography.
In any case, Monte Carlo tools appear to be very helpful 
for analysing the role of the various parameters defining 
the BSP configurations as well as their results (such as 
overdiagnosis) without involving actual populations and 
avoiding the economical, logistic and ethical problems 
that it usually entails. Even more, changes in the diag-
nostic or procedural methodologies can be included in 
the simulation, thus allowing to anticipate the results of 
the new programmes before their implementation.
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